San Francisco, CA, September 18, 2023 – FlemingMartin is pleased to announce that 89bio, a public, clinical-stage biopharmaceutical company tackling severe liver and cardio-metabolic diseases, has hired Annie Chang as their Vice President of Investor Relations and Corporate Communications.
Annie is a dynamic investor relations and corporate communications professional with 15 years of diverse experience across the biotech, tech, and finance industries. In addition to IR and Communications, Annie’s background encompasses investment banking, investment management, corporate development, and M&A. Most recently, Annie served as VP of Investor Relations at Sutro Biopharma for three years, where she acted as a strategic advisor to the CEO and Board. Before Sutro, Annie spent time at Solebury Trout as a VP of Investor Relations working closely with privately-held and publicly-traded companies across the life science ecosystem. Earlier in her career, Annie held roles of increasing responsibility at NIO, Icefield Capital, Yahoo!, and Morgan Stanley.
Annie earned her MBA from INSEAD, and she received her BS in Finance from New York University.
Headquartered in San Francisco, California, 89bio is a public, clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Venture Capital Firms, and CEOs to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. flemingmartin.com